



Short communication

Exercise intolerance associated with impaired oxygen extraction in patients with long COVID

Anna Norweg^{a,*}, Lanqiu Yao^b, Scott Barbuto^a, Anna S. Nordvig^c, Thaddeus Tarpey^b, Eileen Collins^d, Jonathan Whiteson^e, Greg Sweeney^e, Francois Haas^e, John Leddy^f

^a Department of Rehabilitation and Regenerative Medicine, Columbia University College of Physicians and Surgeons, USA

^b Department of Population Health, New York University Grossman School of Medicine, USA

^c Department of Neurology, Weill Cornell Medicine, USA

^d College of Nursing, University of Illinois At Chicago, Chicago, USA

^e Department of Rehabilitation Medicine, New York University Grossman School of Medicine, USA

^f UBMD Dept of Orthopaedics and Sports Medicine, SUNY Buffalo Jacobs School of Medicine and Biomedical Science, USA



ARTICLE INFO

Keywords:

Long COVID-19
Energy metabolism
Chronotropic intolerance
Post-exertional malaise
Exercise intolerance
Dysautonomia

ABSTRACT

Objective: Chronic mental and physical fatigue and post-exertional malaise are the more debilitating symptoms of long COVID-19. The study objective was to explore factors contributing to exercise intolerance in long COVID-19 to guide development of new therapies. Exercise capacity data of patients referred for a cardiopulmonary exercise test (CPET) and included in a COVID-19 Survivorship Registry at one urban health center were retrospectively analyzed. **Results:**

Most subjects did not meet normative criteria for a maximal test, consistent with suboptimal effort and early exercise termination. Mean O₂ pulse peak % predicted (of 79 ± 12.9) was reduced, supporting impaired energy metabolism as a mechanism of exercise intolerance in long COVID, n = 59. We further identified blunted rise in heart rate peak during maximal CPET. Our preliminary analyses support therapies that optimize bioenergetics and improve oxygen utilization for treating long COVID-19.

1. Introduction

Long COVID-19 occurs in approximately 10 – 20% of survivors of COVID-19, representing about 10 – 20 million global long-term cases (Vehar et al., 2021; Wise, 2021). It is characterized by persistent, multi-organ symptoms beyond 3 months from onset of acute illness. (Soriano et al., 2021) Chronic fatigue, exercise intolerance, post-exertional malaise (PEM), and orthostatic intolerance are some of the more debilitating symptoms of long COVID-19. Exercise intolerance is defined as the “inability to exercise to near age-appropriate maximum heart rate due to exacerbation of symptoms”. (Leddy et al., 2021), p.3 PEM is defined as “inappropriate loss of physical and mental stamina, rapid muscular and cognitive fatigability, tendency for symptoms to

worsen, or prolonged exacerbation of patient’s baseline symptoms after physical, cognitive, and orthostatic stress” (Jason et al., 2021), p.238 PEM symptom exacerbation can be immediate after exertion or can be delayed for 24–72 h.

Underlying mechanisms of exercise intolerance in the chronic or “long-hauler” phase of COVID-19 are likely multifactorial. Impaired mitochondrial function (regulation of energy metabolism) and oxygen metabolic homeostasis (e.g., oxygen transportation and sensing) may be a significant contributing factors to fatigue and impaired exercise tolerance in long COVID (Astin et al., 2023). Impaired autonomic nervous system (ANS) function can result in dysregulated heart rate, blood pressure, respiratory, gastrointestinal, thermoregulatory, and bladder functions. Exercise intolerance may be associated with blunted or

Abbreviations: AT, Anaerobic threshold; COVID-19, Coronavirus disease 2019; CPET, Cardiopulmonary exercise testing; FEV₁, Forced expiratory volume in one second; FVC, Forced vital capacity; HR, Heart rate; HRR, Heart rate reserve; IQR, Interquartile range; ICU, Intensive care unit; ME/CFS, Myalgic encephalomyelitis/chronic fatigue syndrome; MET, Metabolic equivalent; PEF, Peak expiratory flow; PEM, Post-exertional malaise; RER, Respiratory exchange ratio; RPP, Rate-pressure product; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SD, Standard deviation; V_E/V_{CO2}, Ventilatory equivalent for CO₂; VO₂, Oxygen consumption.

* Correspondence to: Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, 617 West 168th Street, New York, NY 10032, USA.

E-mail address: amn2212@cumc.columbia.edu (A. Norweg).

<https://doi.org/10.1016/j.resp.2023.104062>

Received 14 January 2023; Received in revised form 8 April 2023; Accepted 16 April 2023

Available online 17 April 2023

1569-9048/© 2023 Elsevier B.V. All rights reserved.

decreased age-predicted maximal heart rate (HR), also called chronotropic intolerance (CI). CI is diagnosed by inability to meet 80% of age-derived HR_{peak} during a noninvasive maximal cardiopulmonary exercise testing (CPET) (Jimeno-Almazán et al., 2021). The aim of our observational, retrospective study was to explore factors contributing to exercise intolerance in long COVID-19 to guide development of new therapies.

2. Methods

Patients recovered from positive, acute COVID-19 infection and referred for cardiopulmonary exercise testing (CPET) at an urban Ambulatory Care Center, between March and August 2020, were included in a COVID-19 Survivorship Registry. Inclusion criteria were at least 21 years of age with positive COVID-19 infection in electronic medical record. Participants' exercise capacity was compared to reference normative data. Statistical differences in the cohort were calculated between patient sub-groups based on standard % predicted peak oxygen

Table 1
Differences based on VO_2 Maximum Exercise Capacity Criterion.

	Total Sample	VO_2 peak > 84% pred	VO_2 peak \leq 84% pred	p-value
n (%)	59	35 (59)	24 (41)	
Age, years	53.9 (15)	54.7 (15.8)	52.7 (14)	0.61
Sex (%)				0.371
Male	34 (57.6)	18 (51.4)	16 (66.7)	
Female	25 (42.4)	17 (48.6)	8 (33.3)	
Race (%)				0.183
White	29 (50.0)	21 (61.8)	8 (33.3)	
African American	10 (17.2)	5 (14.7)	5 (20.8)	
Asian	5 (8.6)	1 (2.9)	4 (16.7)	
Chinese	2 (3.4)	2 (5.9)	0 (0.0)	
Filipino	4 (6.9)	2 (5.9)	2 (8.3)	
Latino	6 (10.3)	2 (5.9)	4 (16.7)	
Other	2 (3.4)	1 (2.9)	1 (4.2)	
Weight loss post-COVID-19 (lbs.)	14.4 (14.3)	17.4 (14.4)	15 (14.5)	0.457
Hospitalized (%)	32 (56.1)	18 (52.9)	14 (60.9)	0.749
Inpatient rehabilitation (%)	21 (36.8)	12 (35.3)	9 (39.1)	0.988
ICU (%)	23 (41.8)	12 (37.5)	11 (47.8)	0.625
Mechanical ventilation (%)	20 (36.4)	11 (34.4)	9 (39.1)	0.938
Days from hospital discharge	69 (57–143)	64 (55.2–98)	125 (69–146)	0.211
Days from positive COVID-19 test diagnosis	167 (68.8)	159.3 (68.1)	177.8 (70)	0.332
Length of stay, days	38.1 (26.9)	32.8 (23.2)	44.9 (30.7)	0.249
Days in ICU	13.5 (10.3)	12.9 (11.4)	16 (5.7)	0.614
FVC % pred	74 (64–90)	80 (69–94)	63.5 (54.2–81.5)	0.003
FEV ₁ % pred	82.2 (18.5)	88.1 (15.9)	73.6 (18.8)	0.004
FEV ₁ /FVC	85.2 (8)	84.5 (7.7)	86.3 (8.4)	0.407
PEF % pred	95 (83.5–106.5)	102 (91–110)	85 (77–95)	0.001
FEF 25–75%	100 (82.5–118.5)	102 (85.5–118.5)	96.5 (80.2–117)	0.436
Performance				
VO_{2peak} (ml/kg/min)	21.8 (6.1)	24.3 (5.2)	18.2 (5.6)	< 0.001
VO_{2peak} (ml/kg/min) % pred	89.2 (22.2)	104.2 (12.5)	67.4 (13.1)	< 0.001
VO_2 AT (ml/kg/min)	12.2 (3)	13.3 (2.7)	10.6 (2.7)	< 0.001
Anaerobic threshold (AT/predicted VO_2 max x 100)	57.4 (8.8)	55.7 (8.1)	50.0 (9.2)	0.069
Actual MET	6.2 (1.7)	7 (1.5)	5.2 (1.6)	< 0.001
MET pred	7.7 (2.8)	8.6 (2.4)	6.5 (2.8)	0.004
Test Duration (n = 38)	7.44 (1.92)	7.88 (1.84)	6.41 (1.76)	0.031
Test Duration % pred (n = 38)	79.60 (22.26)	87.85 (20.55)	60.10 (11.55)	< 0.001
Circulation				
Peak systolic	162.4 (24.2)	168.7 (23.4)	153.2 (22.7)	0.017
Peak diastolic	80 (70–80)	80 (70–80)	70 (66–80)	0.242
HR reserve (beats/min)	16 (3.5–27.5)	6 (0–17.5)	27 (17–44.5)	< 0.001
HR peak	149.2 (23.1)	156.7 (19)	138.3 (24.5)	0.004
HR % pred	89.8 (11.4)	94.9 (9.2)	82.3 (10.4)	< 0.001
HR AT	105.9 (14.9)	107.8 (13.4)	103.2 (16.7)	0.267
HR peak % pred	71.5 (8.3)	69.1 (7.5)	75 (8.2)	0.007
Cardiovascular Function				
Peak VO_2 /HR	11.6 (9.9–13.7)	12.4 (10.9–14.4)	10.7 (9.1–11.9)	0.002
O_2 pulse peak % pred	79 (12.9)	78.6 (13.7)	79.5 (11.7)	0.772
VO_2 /HR AT	9.4 (2.7)	10.3 (2.7)	8.2 (2.2)	0.002
VO_2 /HR % pred	99.3 (21)	110.6 (13.5)	82.8 (19)	< 0.001
Rate-pressure product (RPP)	22,700 (18,186–26767.5)	23,940 (22,176–28730)	18,144 (15,865–23430)	< 0.001
Ventilation				
Peak V_E (L/min)	71.5 (24.4)	80.2 (22)	58.8 (22.4)	< 0.001
V_E % pred (SD)	81 (21.3)	87.1 (18.6)	72 (22.3)	0.009
V_E reserve (range)	18 (4–29.5)	17 (0–24.5)	23 (5.8–37.2)	0.107
Gas exchange				
V_E/V_{CO_2} AT	31.8 (29.1–35.6)	31.6 (28.6–34.6)	32.5 (29.9–38.7)	0.208
RER peak	1.11 (0.12)	1.13 (0.10)	1.08 (0.13)	0.099
SpO ₂ minimum	95 (94–97)	95 (94–97)	95 (92.8–98)	0.938

Note. AT: at threshold. HR: heart rate. Lbs: pounds. FVC: forced vital capacity. Min: minutes. O_2 : oxygen; PEF: peak expiratory flow. pred: predicted. RER: respiratory exchange ratio at end of test. RPP: rate-pressure product. V_E : minute ventilation. V_E/V_{CO_2} AT: ventilatory equivalent for carbon dioxide. VO_2 : oxygen uptake; VO_2 /HR: oxygen pulse. V_E/V_{CO_2} ratio: ventilatory equivalent for carbon dioxide.

consumption (VO_2 peak). To diagnose CI, we analyzed a subgroup of patients who completed a maximal CPET (defined by an $RER_{peak} > 1.05$ (Radtke et al., 2019)) and who were not admitted to ICU (Davenport et al., 2019). RER is VCO_2/VO_2 (ATS/ACCP, 2003). We also compared subgroups based on gender, since long COVID-19 may be more prevalent in women (Torjesen, 2021).

We evaluated lung function with spirometry and exercise capacity using gold standard CPET on a treadmill (Vyaire Medical, Mettawa, IL) with the Bruce protocol (Myers et al., 1991). In particular, we used the 2012 European Respiratory Society Global Lung Function Initiative's (GLI) prediction equations, with age- and gender-dependent lower limits of normal and validity across different ethnic groups, to calculate lung volume, diffusion, spirometry, and exercise capacity values. (Quanjer et al., 2012)

Past medical history data were collected, including hospital length of stay, need for intensive care unit (ICU), and mechanical ventilation. Quantitative demographic and clinical variables were evaluated using Student's t-test or a Wilcoxon Rank Sum test, depending on whether the given variable was normally distributed. The Shapiro-Wilk test was used to examine the normality of each quantitative variable. Pearson's Chi-square test was used to assess qualitative variables such as gender and race. Statistical significance was considered as a p-value of < 0.05 . The statistical analysis was conducted with R-3.5.1.^a

Normal exercise capacity was defined as $VO_{2peak} > 84\%$ predicted, (ATS/ACCP, 2003) and $> 80\%$ predicted for other exercise parameters

(ATS/ACCP, 2003) We hypothesized that exercise intolerance was associated with impaired oxygen extraction, autonomic dysfunction, and deconditioning in patients with long COVID-19.

3. Results

We collected CPET data on 59 long COVID-19 participants (34 men, 58%) with a mean (SD) age of 53.9 years (15.0). Average (SD) days after positive infection diagnosis was 167 (68.8). 56% of participants had been hospitalized with acute COVID-19, 42% of whom required ICU. 87% of patients in ICU required mechanical ventilation. 82.6% of patients admitted to ICU received inpatient pulmonary rehabilitation compared with only 6.2% of patients hospitalized without ICU stay ($p < 0.001$). Race was a significant social determinant of whether a patient was admitted to the ICU ($p = 0.024$). Except for forced vital capacity (FVC), which was an average of 74% predicted (range: 64–90), mean spirometry values were normal in our sample.

Mean (SD) O_2 pulse peak % predicted was 79 (12.9) (Table 1). Test duration was 79.6 (22.3) % predicted (Table 1). Mean % predicted HR_{peak} was $\leq 75\%$. 24 participants (41%) had reduced exercise capacity, defined by a VO_2 peak $\leq 84\%$ (ATS/ACCP, 2003). Mean VO_2 peak was 89.2% (SD = 22.2%). 18 participants (30.5%) showed high (≥ 34) V_E/V_{CO_2} slope.

Reduced exercise capacity defined as VO_2 peak $\leq 84\%$ pred. Normal exercise capacity defined as VO_2 peak $> 84\%$ predicted.

Table 2
Differences based on VO_2 Maximum in Patients with a Maximal CPET.

	Total Sample	VO_2 peak $> 84\%$ pred	VO_2 peak $\leq 84\%$ predicted	p-value
n (%)	19	13	6	
Age, years	54 (15.9)	52 (18.7)	58.3 (6.2)	0.287
Sex (%)				0.735
Male	9 (47.4)	7 (53.8)	2 (33.3)	
Female	10 (52.6)	6 (46.2)	4 (66.7)	
Race (%)				0.105
FVC % pred	79.8 (15.8)	85.6 (12.9)	67.2 (14.8)	0.028
FEV ₁ % pred	85.4 (14)	91 (9.6)	73.3 (15.1)	0.035
FEV ₁ /FVC	84.3 (6.8)	83.5 (6.1)	85.8 (8.5)	0.57
PEF % pred	98 (17.5)	104.4 (16.8)	84.2 (9.3)	0.004
Performance				
VO_{2peak} (ml/kg/min)	22.6 (7.2)	25.4 (6.2)	16.4 (5.4)	0.008
VO_{2peak} (ml/kg/min) % pred	100 (78–106)	105 (100–108)	72 (58–75.5)	< 0.001
VO_2 AT (ml/kg/min)	12.1 (3.8)	13.5 (3.4)	9.1 (2.8)	0.012
VO_2 AT/peak % pred	54.5 (9.8)	53.5 (9.3)	56.8 (11.2)	0.500
Actual MET	6.4 (2.1)	7.2 (1.8)	4.7 (1.5)	0.011
MET pred	7.9 (3.4)	8.9 (2.9)	5.7 (3.5)	0.083
Test Duration (n = 15)	7.8 (2.3)	8.3 (2.0)	4.5 (0.0)	0.019
Test Duration % pred (n = 15)	86.5 (23.4)	91.4 (20.9)	54.8 (9.9)	0.033
Circulation				
Peak systolic	154.2 (22.8)	159.7 (24.3)	140 (9.4)	0.025
Peak diastolic	71 (70–80)	72 (70–80)	70 (70–72)	0.644
HR reserve (beats/min)	16 (2–25.5)	5 (0–16)	33 (25.2–46.8)	0.002
HR peak	150.3 (24.3)	161.5 (19.7)	126 (12.9)	< 0.001
HR % pred	90.4 (10.9)	96.1 (6.7)	78.2 (7.4)	< 0.001
HR AT	102.6 (13.6)	105.2 (14.4)	97 (10.5)	0.183
HR peak % pred	69 (7.7)	65.5 (6.3)	76.7 (4)	< 0.001
Cardiovascular Function				
Peak VO_2 /HR	11.9 (10.1–13.7)	11.9 (10.7–13.8)	11.2 (9.7–13.3)	0.483
O_2 pulse peak % pred	77.4 (18.9)	79.9 (19.6)	72 (17.4)	0.396
VO_2 /HR AT	9.9 (8.8–11.4)	11.1 (9.3–11.9)	9.4 (6.8–9.9)	0.105
VO_2 /HR % pred	100.9 (15.6)	107.1 (10.7)	87.7 (17.1)	0.039
Rate-pressure product (RPP)	22,764 (17,503.5–27654)	25,110 (22,680–29070)	17,082 (14,850–17290)	0.008
Ventilation				
Peak V_E (L/min)	80.2 (24.2)	87.3 (25.1)	64.7 (13.3)	0.02
V_E % pred	86 (19.5)	88.5 (20.2)	80.5 (18.1)	0.405
V_E reserve (L/min)	14 (2–24.5)	17 (0–24)	10.5 (4–26)	0.86
Gas exchange				
V_E/V_{CO_2} AT	33.4 (7.8)	31.3 (6.8)	38 (8.4)	0.122
RER peak	1.2 (0.1)	1.2 (0.1)	1.1 (0.03)	0.004

Note. AT: Anaerobic threshold. HR: heart rate. Lbs: pounds. FVC: forced vital capacity. Min: minutes. O_2 : oxygen; pred: predicted. PEF: peak expiratory flow. RER: respiratory exchange ratio at end of test. RPP: rate-pressure product. VE: minute ventilation. V_E/V_{CO_2} AT: ventilatory equivalent for carbon dioxide. VO_2 : oxygen uptake; VO_2 /HR: oxygen pulse. V_E/V_{CO_2} ratio: ventilatory equivalent for carbon dioxide.

Only 19 non-ICU participants completed a maximal CPET (Table 2). Mean (SD) HR_{peak} was 69 (7.7) % predicted in this subsample (Table 2), indicating blunted rise in HR (CI, i.e., inability to meet 80% of age derived HR_{peak}) during a maximal CPET (n = 19). (Jimeno-Almazán et al., 2021) In participants who achieved peak volume of oxygen consumed (VO₂) > 84%, mean HR peak % predicted was 65.5%, significantly below normative values.

Reduced exercise capacity defined as VO₂ peak ≤ 84% pred. Normal exercise capacity defined as VO₂ peak > 84% predicted.

Analyzing by sex, only women with reduced exercise capacity (VO₂ peak ≤ 84% pred) had higher mean V_E/V_{CO2} slope of 38.8 at the anaerobic threshold (p = 0.049) compared with women demonstrating normal exercise capacity, which may reflect hyperventilation and ventilatory inefficiency (n = 25). In women only, mean (SD) peak respiratory exchange ratio (RER_{peak}) – the ratio of carbon dioxide metabolic production to oxygen uptake – of 1.0 (0.1) was reduced in the reduced exercise capacity subgroup compared with 1.1 (0.1) in normal exercise capacity subgroup, indicating sub-maximal effort and exertion intolerance (p = 0.038). (ATS/ACCP, 2003; Kim et al., 2016) In contrast to women, reduced exercise capacity was associated with worse pulmonary function values (FVC % pred, p = 0.032; FEV₁% pred and PEF % pred, p = 0.025) only in men, suggesting more severe COVID-19 disease and/or premorbid comorbidity in men.

4. Discussion

This observational study explored contributing factors to exercise intolerance in symptomatic patients with a mean of 6 months post-acute COVID-19 infection. We found a circulatory limitation (mean HRR < 15 beats/min) (ATS/ACCP, 2003) in the VO₂ peak > 84% predicted group. We also found mean O₂ pulse peak % predicted (of 79 ± 12.9) was reduced in our sample (n = 59). O₂ pulse reflects the “amount of O₂ extracted per heartbeat”.^{15,p. 212; 10} O₂ pulse is equal to the product of stroke volume and the arterial-to-mixed venous O₂ content difference [C(a-v)O₂] (ATS/ACCP, 2003). We hypothesize that this impaired circulation and O₂ extraction, and low O₂ pulse (and likely lactic acid accumulation) contributed to early mental and peripheral muscle fatigue and early exercise termination. Impaired energy metabolism and mitochondrial bioenergetics as a mechanism of impaired exercise tolerance in long COVID is novel and similar to ME/CFS (Guntur et al., 2022). Our finding of CI – an indication of impaired autonomic function – may further explain persisting symptoms of long COVID, such as dyspnea and PEM; (Davenport et al., 2019) consistent with another long COVID-19 study (Balady et al., 2010; Jimeno-Almazán et al., 2021).

In our cohort, heart rate (HR) reserve was significantly higher in the reduced exercise capacity subgroup (those with VO₂ peak ≤ 84% predicted), possibly also indicating deconditioning. These participants demonstrated less energy expenditure (METs), shorter test duration, and higher heart rate reserve (1 – (peak heart rate/(220 – age)) × 100; Table 1.

Mean VE reserve (VEmax /MVV) × 100) was 10.5 (4–26) for patients with VO₂ peak ≤ 84% predicted (in maximal CPET, Table 2), possibly also contributing to exercise intolerance and lower RER. A VE reserve of ≥ 15% of ventilatory capacity is considered normal (ATS/ACCP, 2003) Almost a third of subjects showed breathing inefficiency, defined as high (≥ 34) V_E/V_{CO2} slope (Balady et al., 2010). Therefore, a ventilatory limitation may be a contributing factor to exercise intolerance in long COVID.

While a gold standard for defining maximal effort does not exist, a majority (57.6%) of subjects did not meet normative criteria for a maximal test, i.e., RER_{peak} (> 1.05) supporting suboptimal effort. Our findings highlight exertional limitation and a high prevalence of early exercise termination in patients with long COVID-19. Consistent with our hypotheses, exertional limitation may be associated with autonomic dysfunction (CI, reduced peak systolic pressure, and breathing inefficiency) in adults with long COVID. Suboptimal effort (submaximal

tests) was supported by another long COVID study (Motiejunaite et al., 2020).

A single administration of CPET may overestimate the exercise tolerance of patients with long COVID-19 because patients with PEM may not be able to reproduce exercise performance 24 h later (Nelson et al., 2019). We therefore recommend a more comprehensive evaluation of post-exercise recovery with 2-day CPET.

4.1. Limitations

A limitation of our study is that we did not collect data on comorbid medical conditions or quantify symptoms. However, all participants were symptomatic at the time of CPET testing. Timing of CPET varied widely for days post-positive COVID-19 test. Diffusing lung capacity for carbon monoxide (DLCO) data was not measured as a contributing factor in exercise intolerance. Impaired DLCO can persist in adults with long COVID and is associated with symptoms of exertional dyspnea. (Fortini et al., 2022) The heterogeneity of the sample (with the inclusion of both patients post-ICU with mechanical ventilation and those after only mild COVID-19 infection) limited the interpretation of our findings and our ability to characterize patients' ventilatory capacity. We also did not repeat CPET within 24 h to assess PEM and determine subjects' ability to reproduce VO₂ peak.

5. Conclusions

Impaired oxygen extraction, stroke volume (O₂ pulse), and CI were associated with long COVID. Impairments of O₂ uptake, delivery, and ventilation may contribute to persisting symptoms of long COVID-19, especially fatigue, post-exertional malaise, and dyspnea. Our study may help to advance understanding of biomarkers in long COVID and assist with the development of effective treatments. Considering *exercise as medicine*, (Oliveira and Hood, 2019) by improving oxygen metabolism and mitochondrial bioenergetics, tailored sub-symptom, low-intensity aerobic exercise may provide the right stimulus to help to treat long COVID (Guntur et al., 2022; Sorriento et al., 2021; Heo et al., 2023). Exercise improves nitric oxide, a potent vasodilator with anti-coagulant, antiviral, and antioxidant effects (Ricciardolo et al., 2020; Maiorana et al., 2003).

Supplier

R Core Team, 2022; The R Foundation.

Ethics approval

This study was approved by New York University's Institutional Review Board (i20–00909).

Study design

A. Norweg, L. Yao, T. Tarpey; data analyses: L. Yao and T. Tarpey; interpretation of the results: A. Norweg, S. Barbuto, A. Nordvig, E. Collins, and J. Leddy; manuscript writing: A. Norweg, S. Barbuto, A. Nordvig, E. Collins, J. Leddy, L. Yao, T. Tarpey, J. Whiteson, G. Sweeney, and F. Haas.

Funding

This research did not receive any specific grant funding.

Conflict of interest statement

Authors have no conflicts of interest to report.

Data Availability

The authors do not have permission to share data.

Acknowledgements

We acknowledge the assistance of Rany Condos, MD, in developing a Registry of COVID-19 Survivors and obtaining IRB approval of this study at New York University Grossman School of Medicine.

References

- Astin, R., Banerjee, A., Baker, M.R., et al., 2023. Long COVID: mechanisms, risk factors and recovery. *Exp. Physiol.* 108 (1), 12–27.
- Balady, G.J., Arena, R., Sietsema, K., et al., 2010. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation* 122 (2), 191–225.
- Davenport, T.E., Lehnen, M., Stevens, S.R., VanNess, J.M., Stevens, J., Snell, C.R., 2019. Chronotropic intolerance: an overlooked determinant of symptoms and activity limitation in myalgic encephalomyelitis/chronic fatigue syndrome? *Front. Pediatr.* 7, 82.
- Fortini, A., Rosso, A., Cecchini, P., et al., 2022. One-year evolution of DLCO changes and respiratory symptoms in patients with post COVID-19 respiratory syndrome. *Infection* 50 (2), 513–517.
- Guntur, V.P., Nemkov, T., de Boer, E., et al., 2022. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC). *Metabolites* 12 (11).
- Heo, J., Noble, E.E., Call, J.A., 2023. The role of exerkines on brain mitochondria: a mini-review. *J. Appl. Physiol.* (Bethesda, Md: 1985) 134 (1), 28–35.
- Jason, L.A., Holtzman, C.S., Sunnquist, M., Cotler, J., 2021. The development of an instrument to assess post-exertional malaise in patients with myalgic encephalomyelitis and chronic fatigue syndrome. *J. Health Psychol.* 26 (2), 238–248.
- Jimeno-Almazán, A., Pallarés, J.G., Buendía-Romero, Á., et al., 2021. Post-COVID-19 syndrome and the potential benefits of exercise. *Int. J. Environ. Res. Public Health* 18 (10).
- Jimeno-Almazán, A., Pallarés, J.G., Buendía-Romero, Á., Martínez-Cava, A., Courel-Ibáñez, J., 2021. Chronotropic incompetence in non-hospitalized patients with Post-COVID-19 syndrome. *J. Clin. Med.* 10 (22).
- Kim, C., Choi, H.E., Lee, K.H., Kim, Y.J., Lee, S.J., 2016. Influence of low peak respiratory exchange ratio on cardiac rehabilitation in patients with coronary artery disease. *Ann. Rehabil. Med.* 40 (6), 1114–1123.
- 10JR: ATS/ACCP Statement on cardiopulmonary exercise testing. *Am. J. Respir. Crit. Care Med.* 167 2 2003 211 277 ATS/ACCP Statement on cardiopulmonary exercise testing. *American journal of respiratory and critical care medicine.* 2003;167(2): 211–277. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am. J. Respir. Crit. Care Med.* 167 (2), 2003, 211–277.
- Leddy, J.J., Haider, M.N., Noble, J.M., et al., 2021. Management of concussion and persistent post-concussive symptoms for neurologists. *Curr. Neurol. Neurosci. Rep.* 21 (12), 72.
- Maiorana, A., O'Driscoll, G., Taylor, R., Green, D., 2003. Exercise and the nitric oxide vasodilator system. *Sports Med.* 33 (14), 1013–1035.
- Motiejunaite, J., Balagny, P., Arnoult, F., et al., 2020. Hyperventilation: a possible explanation for long-lasting exercise intolerance in mild COVID-19 survivors? *Front. Physiol.* 11, 614590.
- Myers, J., Buchanan, N., Walsh, D., et al., 1991. Comparison of the ramp versus standard exercise protocols. *J. Am. Coll. Cardiol.* 17 (6), 1334–1342.
- Nelson, M.J., Buckley, J.D., Thomson, R.L., Clark, D., Kwiatek, R., Davison, K., 2019. Diagnostic sensitivity of 2-day cardiopulmonary exercise testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *J. Transl. Med.* 17 (1), 80.
- Oliveira, A.N., Hood, D.A., 2019. Exercise is mitochondrial medicine for muscle. *Sports Med. Health Sci.* 1 (1), 11–18.
- Quanjer, P.H., Stanojevic, S., Cole, T.J., et al., 2012. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur. Respir. J.: Off. J. Eur. Soc. Clin. Respir. Physiol.* 40 (6), 1324–1343.
- Radtke, T., Crook, S., Kaltsakas, G., et al., 2019. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *Eur. Respir. Rev.: Off. J. Eur. Respir. Soc.* 28, 154.
- Ricciardolo, F.L.M., Bertolini, F., Carriero, V., Högman, M., 2020. Nitric oxide's physiologic effects and potential as a therapeutic agent against COVID-19. *J. Breath. Res.* 15 (1), 014001.
- Soriano, J.B., Murthy, S., Marshall, J.C., Relan, P., Diaz, J.V., 2021. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect. Dis.*
- Sorriento, D., Di Vaia, E., Iaccarino, G., 2021. Physical exercise: a novel tool to protect mitochondrial health. *Front. Physiol.* 12, 660068.
- Torjesen, I., 2021. Covid-19: middle aged women face greater risk of debilitating long term symptoms. *Bmj* 372, n829.
- Vehar, S., Boushra, M., Ntiamoah, P., Biehl, M., 2021. Post-acute sequelae of SARS-CoV-2 infection: caring for the 'long-haulers'. *Clevel. Clin. J. Med.* 88 (5), 267–272.
- Wise, J., 2021. Long covid: WHO calls on countries to offer patients more rehabilitation. *Bmj* 372, n405.